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Abstract
Background: A significant trend towards increased fusidic acid (FA) resistance among Staphylococcus aureus with
increased duration of use is of concern. The aim of the present study is to investigate the dissemination of fusidic
acid resistance among Staphylococcus aureus clinical isolates.
Methods: The susceptibility of S. aureus isolates to antimicrobial agents was determined by disc-diffusion method. The
minimal inhibitory concertrations(MICs) of fusidic acid and vacomycin for fusidic acid-resisitant isolates were determined
by ager dillution method. FA resistance determinants were determined by PCR and DNA sequencing. SCCmec typing, spa
typing and multi-locus sequence typing were used for the determination of molecular characteristics for S. aureus isolates.
Results: A total of 392 non-duplicate S. aureus isolates including 181 methicillin-resistant S. aureus (MRSA) isolates, which
were isolated from the clinical specimens of patients at a Chinese tertiary hospital from January, 2012 to September, 2013,
were collected for investigating FA resistance. Among 392 S. aureus clinical isolates tested, 56 (14.3 %) with FA MIC values
ranging from 2 μg/ml to ≥128 μg/ml were resistant to FA. The proportions of FA resistance among MRSA and MSSA
isolates were 27.1 % (49/181) and 3.3 % (7/211). There was a trend of rapidly increased FA resistance among S. aureus and
MRSA isolates from 5.2 % and 8.9 % in 2012 to 24.9 % and 45.1 % in 2013. Acquired FA resistance gene, fusB, was present
in 73.2 % (41/56) of FA-resistant S. aureus isolates. fusC and fusA mutation were not found in any of tested isolates. A total
of 9 sequence types (STs) and 12 spa types were identified among the 56 FA-resistant S. aureus isolates. ST5 accounting
for 66.1 % (37/56) was the most prevalent ST. The majority (92.9 %, 52/56) of the isolates tested belonged to clonal
complex 5(CC5). t2460 was the most prevalent spa type, accounting for 67.9 % (38/56) . ST5-MRSA- II-t2460 was
predominant clone, accounting for 75.5 % (37/49) of FA-resistant MRSA isolates and 66.1 % (37/56) of FA-resistant S.
aureus isolates. Five of 7 FA-resistant MSSA isolates belonged to ST630-MSSA.
Conclusion: Increased FA resistance among S. aureus isolates was found in China. fusB was predominant FA resistance
determinant. The spread of CC5 clone, especially novel ST5-MRSA- II-t2460 clone with high-level resistance to FA, was
responsible for the increase of FA resistance.
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Background
Staphylococcus aureus, especially methicillin-resistant S.
aureus (MRSA), is an important and often encountered
human pathogen responsible for many infectious diseases
from mild superficial skin infection to life-threatening dis-
eases, including skin and soft tissue infections (SSTIs),
foreign-body infections, pneumonia, septic arthritis, endo-
vascular infections, osteomyelitis, sepsis, and bloodstream
infections (BSI) in both hospitals and community settings
[1]. Since the first European isolate of MRSA was detected
in 1960s, MRSA with resistance to all available penicillins
and other β-lactam antimicrobial agents has become a
leading cause of nosocomial infections in hospitals and
other healthcare facilities. In addition to β-lactam, MRSA
isolates are often resistant to erythromycin, clindamycin,
aminoglycosides and quinolones. Since the mid-1990s,
however, MRSA isolates are found to be responsible for
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severe infections in individuals lacking risk factors for ex-
posure to the health care system [1, 2]. MRSA infections
has become a global concern [1, 3]. As vancomycin has
relatively clean safety profile and durability against the de-
velopment of resistance, it has been considered to be the
optimal option for the treatment of invasive MRSA infec-
tions [4]. However, the emergence of vancomycin- hetero-
resistant S. aureus (hVRSA), vancomycin-intermediate S.
aureus (VISA) and vancomycin-resistant S. aureus
(VRSA) limits the use of vancomycin for the treatment of
serious MRSA infections [5–7]. In addition, the drawbacks
of vancomycin, including poor tissue penetration, serious
nephrotoxicity and neutropenia and unpredictable synergy
with other antimicrobial agents, also limit the selection of
the alternatives for the treatment of MRSA infections.
Fusidic acid (FA), is an effective agent for the treatment of
SSTIs, acute osteomyelitis, chronic osteomyelitis, vertebral
infection, septic arthritis, and prosthetic and other device
related infections caused by MRSA and methicillin-
susceptible S. aureus (MSSA) [8–10]. FA dose of 250-
500 mg every 8–12 h was recommended for the treatment
of MRSA infections [8]. However, recent study reported
that front-loaded dosing of ≥1200 mg every 12 h (q12h)
has better activity against MRSA infections than non-
front-loaded dosing (600 mg q12 h) [11]. Although FA has
not been approved for use in the USA by the US FDA, this
drug has been widely used in Europe, Canada, Australia
and some Asian countries for decades [8]. FA is a valuable
alternative to vancomycin for the treatment of MRSA in-
fections. In the 1990s, the prevalence of resistance to FA
in S. aureus remained low. But there is a concern that
there is a significant trend towards increased FA resistance
among S. aureus with increased duration of use. In a
surveillance report on FA resistance in 13 European coun-
tries, the prevalence of resistance to FA among S. aureus
isolates was 10.7 %, with the highest resistance rates of
62.4 % among the isolates from Greece [12]. Although
many Asian countries have reported FA resistance among
S. aureus isolates, these data in China are limited. The aim
of the present study is to investigate the dissemination of
fusidic acid resistance among S. aureus clinical isolates
from a tertiary hospital between 2012 and 2013 in
Wenzhou, east China.
Methods
Collection of S. aureus clinical isolates
From Jan. 2012 to Sep. 2013, a total of 392 non-duplicate
S. aureus isolates (single isolate per patient) from the vari-
ous specimens of patients at the first Affiliated Hospital of
Wenzhou Medical University locating in Wenzhou, east
China, were selected for investigating the prevalence of
FA resistance. The numbers of S. aureus isolates included
in 2012 and 2013 were 211 and 181. Isolates were identi-
fied as S. aureus by using Gram’s stain, positive catalase
and coagulase test results, and Vitek microbiology analysis
(BioMérieux, Marcy l’Etoile, France). S. aureus ATCC25923
was used as a control strain for the identification of bac-
teria. Because the present study focused on bacteria, the
Ethics Committee of the first Affiliated Hospital of
Wenzhou Medical University exempted this investiga-
tion from review. Informed consents were required
from patients for sample collection.
Antimicrobial susceptibility testing
S. aureus susceptibilities to penicillin (10 μg), erythro-
mycin (15 μg), clindamycin (2 μg), rifampicin (5 μg), tetra-
cycline(30 μg), linezolid (30 μg), quinupristin/dalfopristin
(15 μg), trimethoprim/sulfamethoxazole (1.25/23.75 μg),
gentamicin (10 μg), ciprofloxacin (5 μg), chloramphenicol
(30 μg), fusidic acid (5 μg) and nitrofurantoin (300 μg)
were determined using the disk diffusion test recom-
mended by the Clinical and Laboratory Standards Insti-
tute (CLSI) [13]. Every assay was replicated for three
times. The mean value was applied for the assay. All disks
were obtained from Oxoid Ltd. Vancomycin MICs for S.
aureus isolates were determined by the agar dilution
method in accordance with the CLSI guidelines [14]. In-
terpretive standards of antimicrobial susceptibility testing
for S. aureus isolates tested was in accordance with the
guidelines provided by CLSI [13]. Initial screening of FA
resistance was performed by disk diffusion method with
5 μg FA containing disks. The isolates with an inhibition
zone ≤17 mm in diameter were further determined for FA
MIC values by an agar dilution method. The interpretive
criterion of FA susceptibility is in accordance with the
European Committee for Antimicrobial Susceptibility
Testing (EUCAST)/ criteria (susceptible, MIC < 2 μg/ml;
resistant, MIC ≥ 2 μg/ml). S. aureus ATCC 25923 and
Escherichia coli ATCC25922 were used as reference
strains for antimicrobial susceptibility testing.
DNA extraction
S. aureus isolates with FA resistance were cultured on
blood agar overnight at 35 °C. Then, three to four bac-
terial colonies were suspended in 150 μl sterile distilled
water with lysostaphin (1 mg/mL) (Sangon, Shanghai,
China) and incubated at 37 °C for an hour. Finally, DNA
was extracted following the instructions of the Gen-
omic DNA Extraction kit (Sangon, Shanghai, China),
stored at −20 °C and prepared for PCR assays.
MRSA identification
A simplex PCR was used for the detection of mecA using
MRSA N315 as positive control strain. The isolates posi-
tive for mecA were identified as MRSA. And cefoxitin disk
diffusion test was also used for the detection of MRSA in
accordance with the guideline provided by the Clinical
and Laboratory Standards Institute (CLSI) [13].
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Detection of FA resistance determinants by PCR
Detection of fusA mutations and acquired FA resistance
determinants including fusB and fusC was detected by
PCR assays with primers and reaction conditions de-
scribed previously [15]. DNA sequencing was used for
the identification of genotypes of acquired FA resistance
determinants. The fusA mutations were determined by
sequencing entire fusA gene.
SCCmec typing
SCCmec typing of MRSA isolates was performed
using a battery of multiplex PCRs as described previ-
ously [16]. The MRSA isolates with unanticipated
fragments or lacking fragments by multiplex PCRs
were defined as non-typeable (NT). MRSA NCTC
10442 (SCCmecI), MRSA N315 (SCCmec II), MRSA
85/2082 (SCCmec III), MRSA JCSC 4744 (SCCmec
IV) and MRSA WZ153 (SCCmec V) were used as
control strains for SCCmec typing.
spa typing
The spa variable repeat region from each S. aureus isolate
was amplified using simplex PCR oligonucleotide primers
as previously described [17, 18]. Following their purifica-
tion and sequencing, spa types were assigned using the
spa database website (http://spaserver.ridom.de).
Multilocus sequence typing (MLST)
MLST typing of S. aureus isolates was performed using
amplification of internal fragments of the seven house-
keeping genes(arcc, aroe, glpf, gmk, pta, tpi and yqil) of
S. aureus as described previously [19]. Following purifi-
cation and sequencing of these genes, the sequences
were compared with the existing sequences available on
the MLST website for S. aureus (http://saureus.mlst.net),
and STs were assigned according to the allelic profiles.
Results and discussion
Prevalence of FA resistance among S. aureus isolates
Among 392 S. aureus isolates tested including 181
MRSA isolates, 56 (14.3 %) with FA MIC values ranging
from 2 to ≥128 μg/ml, including 49 (87.5 %, 49/56)
MRSA and 7 (12.5 %, 7/56) MSSA, were resistant to FA.
The proportions of FA resistance among MRSA and
MSSA isolates were 27.1 % (49/181) and 3.3 % (7/211).
The sources for the isolation of the 56 FA-resistant iso-
lates included sputum (42, 75 %), pus (10, 17.9 %), cath-
eter (1, 1.8 %), blood (1, 1.8 %) and exudates (2, 3.6 %).
Compared with previous reports from China with FA re-
sistance rates of 3.5% (4/116) from Shanghai and 2.2 %
(4/186) from Chinese children with SSTIs [20, 21], the
prevalence of FA resistance among S. aureus clinical iso-
lates in the present study was very high. The resistance
rates to FA among S. aureus isolates are different from
country to country. The resistance rates of S. aureus iso-
lates to FA were very low in the USA (0.3 %) and rela-
tively high in Canada (7.0 %) and Australia (7.0 %) [22].
In an updated surveillance report on FA resistance in 13
European countries, Israel, Italy, Poland, Spain and
Sweden had low rates (1.4–3.1 %), while Greece (62.4 %)
and Ireland (19.9 %) had the highest resistance rates
[12]. In most Asian countries, FA resistance rates are
relatively low (<10 %) [8]. FA resistance was observed
more frequently among MSSA isolates (0.6 %) than
among MRSA isolates from the United States [22]. On
the contrary, the prevalence of FA resistance among
MRSA isolates was significantly higher than that among
MSSA isolates in the present study. There is a significant
trend towards increased FA resistance among S. aureus
since FA has been used widely. In Kuwait, the rate of FA
resistance increased rapidly from 22 % in 1994 to 92 %
in 2004 [23]. There was a trend of rapidly increased FA
resistance among S. aureus and MRSA isolates from 5.2
% and 8.9 % in 2012 to 24.9 % and 45.1 % in 2013 in this
investigation. The MIC values of FA for 56 FA-
resistant isolates were as follows: ≥128 μg/ml, 43;
16 μg/ml, 2; 8 μg/ml, 1; 4 μg/ml, 7; and 2 μg/ml, 3.
In 2012, only 5 S. aureus isolates (45.5 %, 5/11) with
FA MIC value of ≥128 μg/ml were identified. Surpris-
ingly, the FA MIC values for 38 (84.4 %) of 45 FA-
resistant isolates were ≥128 μg/ml in 2013. The
resistance rates of FA-resistant S. aureus, MRSA and
MSSA isolates to antimicrobials tested were showed
in Table 1. All 56 FA-resistant isolates were susceptible
to vancomycin, quinupristin-dalfopristin, linezolid, and
Table 1 Antimicrobial resistance profiles of FA-resistant S.aureus,
MRSA and MSSA isolates
S. aureus (n = 56) MRSA (n = 49) MSSA (n = 7)
Ra(%) R(%) R(%)
Tetracycline 75 81. 28.6
Gentamicin 28.6 30.6 14.3
Penicillin 100 100 100
Clindamycin 89.3 91.8 71.4
Erythromycin 92.9 95.9 71.4
Ciprofloxacin 82.1 87.8 42.9
Linezolid 0 0 0




Nitrofurantoin 0 0 0




Vancomycin 0 0 0
a: R, resistance
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nitrofurantoin. The antimicrobials with the resistance
rates of more than 50 % among FA-resistant S. aureus iso-
lates were penicillin (100 %), erythromycin (92.9 %), clin-
damycin (89.3 %), ciprofloxacin (82.1 %), and tetracycline
(75.0 %), respectively. The resistance rates of the 56 iso-
lates to gentamycin, rifampin, trimethoprim/sulfameth-
oxazole and chloramphenicol were relatively low. In
contrast to the report from Taiwan among which the re-
sistance rate to rimethoprim/sulfamethoxazole among
FA-resistant MRSA isolates was high to 97 % [24], only
4.9 % (4/81) of FA-resistant MRSA isolates were resistant
to this antimicrobial.
Prevalence of FA resistance determinants
Two major FA resistance mechanisms have been reported
in S. aureus, including the alteration of the drug target
site, which is due to mutations in fusA encoding elong-
ation factor G (EF-G) or rplF encoding ribosome protein
L6), and the protection of the drug target site by FusB
family proteins including FusB, FusC, and FusD [8]. In
staphylococci, high-level FA resistance is usually associ-
ated with mutations in fusA encoding EF-G, while low-
level resistance is generally caused by the horizontally
transferable genes including fusB, fusC and fusD [25]. The
spontaneous mutations in fusA lead to modification of the
drug target and reduced susceptibility [26]. The fusB-type
resistance involves the recruitment of an exogenous resist-
ance determinant whose product binds EF-G and protects
it from FA [27]. In this study, the results from PCR and
DNA sequencing demonstrated that acquired resistance
gene, fusB was present in 73.2 % (41/56) of FA-resistant
isolates tested. However, fusC and fusA mutations were
not found in any of tested isolates. The previous
investigation from China found that all 4 clinical isolates
with FA resistance were positive for fusB and negative for
fusC and fusA mutations [20]. These data indicated that
fusB is the predominant determinant responsible for FA
resistance among S. aureus in China. In Netherlands, fusB
was also found to be predominant FA resistance determin-
ant which was detected in about 90 % of FA-resistant S.
aureus isolates [28]. On the contrary, a report from north-
ern Taiwan found that 84 % of FA-resistant MRSA isolates
had fusA mutations and another report from a Taiwanese
hospital found that fusC was the most common FA resist-
ance determinant [15, 24]. S. aureus isolates from
Australia with FA MIC values ranging from 2 to
32 μg/ml were predominantly fusC positive [22]. In
U.S. and European collections, fusC was also more
prevalent than fusB in FA-resistant S. aureus isolates
[12, 22]. In contrast to previous report from Taiwan
among which the distribution of FA resistance deter-
minants including fusA mutations, fusB and fusC was
quite different between MRSA and MSSA groups and
no MRSA isolates carried fusB [15].
Molecular characteristics of FA-resistant S. aureus isolates
The molecular characteristics of FA-resistant S. aureus
isolates were listed in Table 2. A total of 9 STs were
identified among the 56 FA-resistant S. aureus isolates,
among which ST5 accounting for 66.1 % (37/56) was the
most common ST, followed by ST630 (12.5 %, 7/56).
Only 3 MRSA isolates belonged to ST239 which is the
predominant ST in China. The STs for two isolates were
not identified. The antimicrobial resistance profiles of
ST5 and ST239 FA-resistant MRSA isolates were
showed in Table 3. The clonal complex 5 (CC5) was the
Table 2 Molecular characteristic of FA-resistant S.aureus isolates
CCa (No.) STsb (No.) spa types (No.) MRSA (No.) MSSA (No.) SCCmec (No.) fusB (No.) fusC (No.) FA MICs (No.)
5(52) ST5(37) t2460(37) 37 0 II(36)III(1) 32 0 ≥128(36);4(1)
ST630(7) t4549(3) 2 1 III(1)V(1) 1 0 2(1);4(1);16(1)
t377(2) 0 2 1 0 4(1);16(1)
t257(1) 0 1 0 0 4(1)
t2196(1) 0 1 1 0 2(1)
ST239(3) t030(3) 2 1 III(2) 2 0 ≥128(2); 4(1)
ST25(2) t078(2) 2 0 II(2) 1 0 ≥128(2)
ST15(1) t2460 1 0 II 0 0 4(1)
ST72(1) t664 1 0 III 0 0 ≥128(1)
ST2831(1) t030 1 0 III 1 0 2(1)
7(1) ST7(1) t091(1) 0 1 0 0 ≥128(1)
59(1) ST59(1) t437 1 0 V 1 0 8(1)
Singleton(2) NT(2) t11497(1) 1 0 II 0 0 4(1)
t5137(1) 1 0 III 1 0 ≥128(1)
a: CC, clone complex; b: ST, sequence type
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predominant CC, accounting for the majority (92.9 %,
52/56) of the isolates tested. Twelve spa types were iden-
tified among the 56 FA-resistant S. aureus isolates,
among which t2460 (67.9 %, 38/56) was the most preva-
lent spa type. The spa types for 5 isolates were not iden-
tified. t2460 was identified among 43.9 % of MRSA
isolates from 3 intensive care units at a Korean tertiary
hospital in 2007–2008 [29]. Among the 49 MRSA iso-
lates, 40, 7 and 2 harbored SCC mec types II, III and V,
respectively.
In the present study, ST5-MRSA- II-t2460 was
predominant clone, accounting for 75.5 % (37/49) of FA-
resistant MRSA isolates and 66.1 % (37/56) of FA-
resistant S. aureus isolates. ST5-MRSA- II is usually
associated with t002 [30]. ST5-MRSA- II-t002 was one
of two major clones in China [30]. However, ST5-
MRSA- II was linked to t2460 in this study. This fairly
unusual clone was only found among 6 MRSA isolates
from Shanghai in China [30]. FA MIC values for 36 of
37 ST5-MRSA- II-t2460 isolates were ≥128 μg/ml. ST5-
MRSA- II-t2460 clone first emerged in 2012. However,
this newly emerging clone with FA resistance increased
dramatically in 2013, accounting for 77.8 % (35/45) of
FA-resistant isolates. The origin of 35 isolates belonged
to ST5-MRSA- II-t2460 in 2013 was confined to only 4
wards including neurosurgery ward (28 isolates), ortho-
paedic ward (three isolates), intensive care unit (three
isolates) and hematology ward (one isolate), indicating
that outbreak of infections caused by this newly clone
has occurred in our hospital, mainly in neurosurgery
ward. Clonal spread is responsible for the increase in FA
resistance in UK, France and other European countries
[31, 32]. CC80-MRSA-IV clone carrying fusB has made a
major contribution to the prevalence of FA resistance
among MRSA isolates in Europe [25]. The highest
prevalence of FA resistance in 2013 in this investigation
was associated with the spread of ST5-MRSA- II-t2460
clone with high-level FA resistance. Among 7 FA-
resistant MSSA isolates, 5 belonged to ST630-MSSA.
Conclusions
In conclusion, increased FA resistance among S. aureus
isolates was found in China. fusB was predominant FA
resistance determinant. The spread of CC5 clone, espe-
cially novel ST5-MRSA- II-t2460 clone with high-level
resistance to FA, was responsible for the increase of FA
resistance.
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